MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$12,973M
Net Income
$3,317M
Net Profit Margin
25.57%
EPS
$1.62
Unit: Million (M) dollars
Revenue Breakdown
Revenues
Alliance And Other Revenues
Revenue Breakdown
Net Product Sales
Other Revenues
Alliance Revenues
Revenue Breakdown
Eliquis
Opdivo
Orencia
Others
Revenue Breakdown
US
Non Us
Other Region
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
12,973
11,489
12,502
12,222
Cost of products sold
3,726
3,421
4,096
3,435
Selling, general and administrative
1,826
1,617
2,181
1,789
Research and development
2,959
2,649
2,586
2,528
Acquired iprd
0
94
1,392
633
Amortization of acquired intangible assets
437
437
826
831
Interest expense
407
411
432
480
Royalty income - divestitures (note 4)
0
0
285
286
Royalty and licensing income (note 4)
186
195
396
276
Investment income
101
104
148
161
Provision for restructuring (note 6)
56
5
132
75
Litigation and other settlements
-5
-4
-11
-165
Loss on debt redemption (note 10)
-
-
-89*
-
Acquisition expense
-
-
4
0
Contingent consideration
0
-
281*
0
Intangible asset impairment
-
-
-
0
Equity investment (gains)/losses, net (note 9)
114
134
190
190
Integration expenses (note 6)
17
19
38
36
Divestiture (gains)/losses (note 4)
138
-
-
-
Other
6
-27
19
-48
Other (income)/expense, net
61
-32
51
108
Total expenses
8,887
8,250
11,032
9,108
Earnings/(gain) before income taxes
4,086
3,240
1,469
3,114
Income tax provision
770
561
384
919
Net earnings/(loss)
3,316
2,678
1,085
2,195
Noncontrolling interest
-1
1
0
-6
Net earnings/(loss) attributable to bms
3,317
2,677
1,087
2,201
Basic EPS
1.62
1.31
0.534
1.08
Diluted EPS
1.62
1.31
0.533
1.08
Basic Average Shares
2,042,000,000
2,038,000,000
2,034,000,000
2,036,000,000
Diluted Average Shares
2,048,000,000
2,047,000,000
2,039,000,000
2,039,000,000
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
4
Revenues
$18,179M
(-18.04%↓ Y/Y)
Net Product Sales
$12,588M
(5.70%↑ Y/Y)
Alliance And Other
Revenues
$385M
Total gtn adjustments
-$5,592M
(45.56%↑ Y/Y)
Total revenues
$12,973M
(5.74%↑ Y/Y)
Royalty and licensing
income (note 4)
$186M
(14.81%↑ Y/Y)
Chargebacksandcashdiscounts
-$2,372M
(30.38%↑ Y/Y)
Medicaidand
Medicarerebates
-$1,759M
(61.05%↑ Y/Y)
Other Rebates Returns
Discounts And Adjustments
-$1,460M
Divestiture (gains)/losses
(note 4)
$138M
Equity investment
(gains)/losses, net (note 9)
$114M
(618.18%↑ Y/Y)
Investment income
$101M
(-27.34%↓ Y/Y)
Other
$6M
(-71.43%↓ Y/Y)
Earnings/(gain) before income
taxes
$4,086M
Total expenses
$8,887M
(-15.33%↓ Y/Y)
Other
(income)/expense, net
$61M
(112.35%↑ Y/Y)
Interest expense
$407M
(-16.08%↓ Y/Y)
Provision for
restructuring (note 6)
$56M
(-74.89%↓ Y/Y)
Integration expenses (note
6)
$17M
(-46.88%↓ Y/Y)
Litigation and other
settlements
-$5M
(-400.00%↓ Y/Y)
Net
earnings/(loss)
$3,316M
(152.55%↑ Y/Y)
Noncontrolling interest
-$1M
(-150.00%↓ Y/Y)
Income tax provision
$770M
(67.39%↑ Y/Y)
Cost of products sold
$3,726M
(10.50%↑ Y/Y)
Research and development
$2,959M
(14.69%↑ Y/Y)
Selling, general and
administrative
$1,826M
(6.60%↑ Y/Y)
Amortization of acquired
intangible assets
$437M
(-47.35%↓ Y/Y)
Net
earnings/(loss) attributable to...
$3,317M
(153.21%↑ Y/Y)
Buy us a coffee
bms-rebrand-logo-svg
BRISTOL MYERS SQUIBB CO (BMY)
bms-rebrand-logo-svg
BRISTOL MYERS SQUIBB CO (BMY)
Show more